FDA Inspection 1298662 — John R. Vanderzyl, M.D.
The FDA completed an inspection of John R. Vanderzyl, M.D. on Jan 9, 2026 in Sugar Land, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 9, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Sugar Land, TX (United States)
Additional details
Clinical Investigator (CI)